ArticleJournal of cancer research and clinical oncology2024

PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.

Xueting Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.